BIOC Biocept, Inc. Stock Quote

BIOC [NASD]

Healthcare | Diagnostics & Research | USA

Index	-	P/E	-	EPS (ttm)	-0.16	Insider Own	0.04%	Shs Outstand	16.84M	Perf Week	-7.79%
Market Cap	22.31M	Forward P/E	-	EPS next Y	-1.19	Insider Trans	-7.11%	Shs Float	16.84M	Perf Month	-19.77%
Income	-2.80M	PEG	-	EPS next Q	-0.14	Inst Own	13.20%	Short Float	1.85%	Perf Quarter	-44.09%
Sales	61.20M	P/S	0.36	EPS this Y	87.30%	Inst Trans	-2.68%	Short Ratio	2.75	Perf Half Y	-63.50%
Book/sh	2.23	P/B	0.64	EPS next Y	-783.30%	ROA	-5.10%	Target Price	9.50	Perf Year	-68.65%
Cash/sh	1.84	P/C	0.77	EPS next 5Y	40.00%	ROE	-8.50%	52W Range	1.43 - 4.97	Perf YTD	-60.77%
Dividend	-	P/FCF	10.62	EPS past 5Y	79.90%	ROI	-6.30%	52W High	-71.43%	Beta	0.66
Dividend %	-	Quick Ratio	3.70	Sales past 5Y	80.20%	Gross Margin	38.30%	52W Low	-0.70%	ATR	0.12
Employees	174	Current Ratio	3.90	Sales Q/Q	-24.30%	Oper. Margin	-3.80%	RSI (14)	31.75	Volatility	9.20% 7.62%
Optionable	Yes	Debt/Eq	0.07	EPS Q/Q	-168.50%	Profit Margin	-4.60%	Rel Volume	0.96	Prev Close	1.54
Shortable	Yes	LT Debt/Eq	0.04	Earnings	Mar 31 AMC	Payout	-	Avg Volume	113.27K	Price	1.42
Recom	2.00	SMA20	-11.99%	SMA50	-24.82%	SMA200	-54.54%	Volume	109,121	Change	-7.79%

Nov-14-17

Reiterated

Chardan Capital Markets

Buy

$2.50 → $1.50

Jun-02-17

Initiated

Chardan Capital Markets

Buy

$2.50

Jun-06-16

Initiated

ROTH Capital

Buy

$1.20

Aug-19-15

Initiated

H.C. Wainwright

Buy

Jun-03-14

Initiated

Aegis Capital

Buy

$16

May-16-22 04:05PM	Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q Business Wire
Apr-08-22 04:05PM	Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Apr-06-22 08:00AM	Biocept Reports 2021 Fourth Quarter and Full Year Financial Results Business Wire
Mar-31-22 06:15PM	Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance Business Wire
Mar-18-22 08:00AM	Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022 Business Wire
Mar-08-22 08:17AM	Biocept Appoints Philippe Marchand as Chief Operating Officer Business Wire
Mar-04-22 08:00AM	Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-22-22 04:17PM	Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer Business Wire -6.25%
Feb-18-22 04:54AM	Biocept, Inc. (NASDAQ:BIOC) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? Simply Wall St. -5.88%
Feb-16-22 04:05PM	Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer Business Wire
Feb-10-22 08:17AM	Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer Business Wire
Jan-21-22 08:00AM	Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant Business Wire
Jan-07-22 09:40AM	Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year? Zacks
Jan-04-22 08:00AM	Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10 Business Wire
Dec-09-21 08:17AM	Biocepts CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain Business Wire
Dec-03-21 06:49AM	Quest Diagnostics (DGX) Expands Testing Suite With NGS Test Zacks
Nov-22-21 01:56PM	Clinical Validation is Completed for New COVID-19 Assay Designed by AEGEA Biotechnologies; Test Quantifies Viral Load to Determine Infection Level and Disease Progression PR Newswire
08:17AM	Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season Business Wire
Nov-18-21 02:45PM	CORRECTING and REPLACING Biocepts CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer Business Wire
Nov-15-21 04:05PM	Biocept Reports Third Quarter 2021 Financial Results Business Wire
Nov-09-21 08:17AM	Study Shows Biocepts Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations Business Wire
Nov-08-21 08:00AM	Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021 Business Wire
Oct-06-21 08:00AM	Biocept to Present at the LD Micro Main Event on October 13 Business Wire
Sep-29-21 01:28PM	Biocept: A New Diagnostic Approach to Improve the Lives of Cancer Patients Benzinga
Sep-22-21 08:17AM	Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic Business Wire
07:00AM	Biocept Invites You to Join Us at the Benzinga Healthcare Small Cap Conference Newsfile
Sep-21-21 08:17AM	Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations Business Wire
Sep-07-21 08:00AM	Biocept to Present at Four Virtual Investor Conferences in September Business Wire
Aug-31-21 08:00PM	Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-22-21 08:17AM	This Analyst Just Made A Massive Upgrade To Their Biocept, Inc. (NASDAQ:BIOC) Earnings Forecasts Simply Wall St.
Aug-19-21 11:37AM	Investors React Positively To Study Data Of Biocept's Cerebrospinal Fluid Assay Benzinga
08:34AM	Biocepts CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer Business Wire
Aug-17-21 11:22AM	Biocept Stock Drops Despite Clocking Q2 Sales Of $12M Benzinga -9.76%
Aug-16-21 04:05PM	Biocept Reports Second Quarter 2021 Financial Results Business Wire -5.25%
Aug-09-21 08:00AM	Biocept to Report Second Quarter 2021 Financial Results and Host Investor Conference Call on August 16, 2021 Business Wire
Aug-03-21 08:17AM	Biocept Names David Karlander as Senior Vice President of Commercial Operations Business Wire
Jul-21-21 08:17AM	Medicare Issues Local Coverage Determination for Biocepts Target Selector Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells Business Wire
Jul-20-21 08:17AM	Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman Business Wire
Jul-19-21 08:00AM	Biocept to Participate in Two July Investment Conferences Business Wire
Jul-06-21 08:27AM	Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers Business Wire
Jun-28-21 08:05AM	Biocept Joins the Russell Microcap® Index Business Wire
Jun-22-21 08:17AM	Biocept to Collaborate with Quest Diagnostics to Provide Advanced NGS-Based Liquid Biopsy Testing for Patients with Lung Cancer Business Wire +5.48%
06:44AM	Biocept Jumps on Quest Accord to Offer Lung Cancer Testing TheStreet.com
Jun-15-21 08:17AM	Biocept Receives More Than 420,000 Samples During First Year of Offering COVID-19 Testing Service Business Wire
Jun-09-21 08:37AM	Biocept and CLEARED4 Collaborate to Develop New Service for Managing COVID-19 Testing and Results Reporting for Biocept Customers Business Wire +6.19%
Jun-03-21 08:00AM	Biocept to Present at the LD Micro Virtual Invitational XI Conference on June 9, 2021 Business Wire
Jun-02-21 04:05PM	Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-12-21 04:05PM	Biocept Reports First Quarter 2021 Financial Results Business Wire
02:30PM	Biocept, Inc. to Host Earnings Call ACCESSWIRE
May-05-21 08:00AM	Biocept to Report First Quarter 2021 Financial Results and Host Investor Conference Call on May 12, 2021 Business Wire
Apr-28-21 08:17AM	Biocept to Supply COVID-19 Testing Through Partnership With the Foundation for California Community Colleges Business Wire
Apr-21-21 08:17AM	Biocept Announces Full Commercial Launch of CNSide Cerebrospinal Fluid Assay to Address Unmet Needs for Patients with Metastatic Brain Cancer Business Wire
Apr-14-21 08:05AM	Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date Business Wire
Apr-07-21 04:05PM	Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System Business Wire
Apr-01-21 05:00PM	Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
08:05AM	Biocept to Host Key Opinion Leader Webinar on April 8 to Discuss its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System Business Wire
Mar-30-21 08:06AM	The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga
Mar-29-21 04:32PM	Biocept: Q4 Earnings Insights Benzinga -9.33%
04:05PM	Biocept Reports 2020 Fourth Quarter and Full Year Financial Results Business Wire
02:30PM	Biocept, Inc. to Host Earnings Call ACCESSWIRE
Mar-27-21 04:18AM	Here's Why We're Watching Biocept's (NASDAQ:BIOC) Cash Burn Situation Simply Wall St.
Mar-22-21 08:00AM	Biocept to Report 2020 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 29, 2021 Business Wire
Mar-16-21 11:41AM	3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy Benzinga
Mar-09-21 07:00AM	Biocept to Participate in Three Virtual Investment Conferences in March Business Wire +7.84%
Mar-03-21 04:05PM	Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Mar-02-21 11:45AM	Biocept, Aegea Bio Ink COVID-19 Test Supply Agreement SmarterAnalyst
08:07AM	Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load Business Wire
Feb-23-21 12:35PM	Biocept Inks Research Pact With Protean BioDiagnostics For Target Selector Kit Advantages In Lung Cancer Benzinga -8.80%
08:07AM	Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocepts Target Selector Assay Kit for Non-Small Cell Lung Cancer Patients Business Wire
Feb-16-21 08:00AM	Study Shows Biocepts Target Selector Detects Mutations in "Quantity Not Sufficient" Specimens in Non-Small Cell Lung Cancer Patients Business Wire +8.47%
Feb-03-21 08:00AM	Biocept Provides Update on COVID-19 Testing with More than 250,000 Samples Received Business Wire
Feb-02-21 04:05PM	Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-23-21 02:03AM	Loss-Making Biocept, Inc. (NASDAQ:BIOC) Expected To Breakeven In The Medium-Term Simply Wall St.
Jan-12-21 08:00AM	Biocept Issues Letter to Stockholders Business Wire
Jan-04-21 08:05AM	Biocept to Present at H.C. Wainwright Virtual BioConnect Conference PR Newswire +6.76%
Dec-31-20 05:29PM	Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Dec-30-20 08:05AM	Biocept Enters into Laboratory Services Agreements with Two Southern California Regional Independent Physician Associations PR Newswire
Dec-14-20 08:00AM	Biocept Provides Business Update PR Newswire
Dec-10-20 08:00AM	Biocept's Target Selector Liquid Biopsy Demonstrated High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center PR Newswire +24.68%
Dec-01-20 11:30AM	While The U.S. Faces Insufficient COVID-19 Testing Volume, EIR Healthcare Launches MedModLabs to Expand Access Immediately PR Newswire
Nov-20-20 08:00AM	Study Shows Biocept's Assays are Viable and Sensitive for Detecting Tumor Cells and Biomarkers in the Cerebrospinal Fluid of Patients with Breast and Lung Cancer that has Metastasized to the Central Nervous System PR Newswire
Nov-17-20 08:05AM	Results from Study Using Biocept's Target Selector Testing to Monitor Breast Cancer Disease Progression to be Presented at 2020 SABCS® PR Newswire
Nov-16-20 06:47PM	Is Biocept Stock a Buy Right Now? This Is What You Need to Know TipRanks
Nov-14-20 07:52AM	Industry Analysts Just Made An Incredible Upgrade To Their Biocept, Inc. (NASDAQ:BIOC) Revenue Forecasts Simply Wall St.
Nov-12-20 04:05PM	Biocept Reports Third Quarter 2020 Financial Results PR Newswire +24.95%
02:30PM	Biocept, Inc. to Host Earnings Call ACCESSWIRE
08:05AM	Biocept Provides Update on COVID-19 Testing with More than 100,000 Samples Received PR Newswire
Nov-09-20 08:05AM	Biocept Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells PR Newswire
Nov-05-20 08:05AM	Biocept Awarded Broad Japanese Patent for the Use of Binding Entities in Combination with any Solid Surface to Capture and Detect any Target of Interest, including CTCs, from any Sample Type PR Newswire
Nov-04-20 08:00AM	Biocept to Release Third Quarter 2020 Financial Results and Host Investor Conference Call on November 12, 2020 PR Newswire
Oct-29-20 08:05AM	Biocept Provides Update on COVID-19 Testing with More than 80,000 Samples Received PR Newswire
Oct-21-20 08:00AM	Biocept Appoints Samuel D. Riccitelli to its Board of Directors PR Newswire
Oct-06-20 08:00AM	Biocept Provides Update on COVID-19 Testing with More than 50,000 Specimens Received PR Newswire
Oct-05-20 08:00AM	Study Shows Biocept's Target Selector May Provide a More Robust Method for Detecting Lung Cancer Metastasis in Cerebrospinal Fluid than Cytology PR Newswire +5.05%
Oct-01-20 08:00AM	Biocept to Present Study Results from Target Selector Testing in the Cerebrospinal Fluid of Patients with Lung Cancer at the IASLC Liquid Biopsy Meeting PR Newswire
Sep-24-20 08:48AM	Is Biocept (NASDAQ:BIOC) In A Good Position To Invest In Growth? Simply Wall St.
Sep-23-20 08:00AM	Biocept Announces the Award of Japanese Patent for Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Cell Mutations in Tissue, Blood and Cerebrospinal Fluid PR Newswire -8.04%
Sep-21-20 06:21PM	Biocepts PCR Testing Remains a Key Piece of the COVID-19 Puzzle; Analyst Says Buy TipRanks
08:00AM	Biocept Announces that Highmark Has Made a Positive Coverage Determination on Target Selector Liquid Biopsy PR Newswire
Sep-16-20 08:00AM	Biocept Provides COVID-19 Testing Update with More than 35,000 Specimens Received PR Newswire +9.07%

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. It has a partnership with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HALE DAVID F	Director	Dec 09	Sale	4.06	374	1,519	101	Dec 10 05:04 PM
HALE DAVID F	Director	Dec 09	Sale	4.07	71	289	796	Dec 10 05:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience